Related Experiment Video
Updated: May 25, 2026

Development of a Negative Selectable Marker for Entamoeba histolytica
Published on: December 12, 2010
Identification of Potent and Selective Inhibitors of Acanthamoeba: Structural Insights into Sterol 14α-Demethylase as
Tatiana Y Hargrove1, David C Lamb2, Zdzislaw Wawrzak3
1Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Abstract:
Acanthamoeba are free-living pathogenic protozoa that cause blinding keratitis, disseminated infection, and granulomatous amebic encephalitis, which is generally fatal. The development of efficient and safe drugs is a critical unmet need. Acanthamoeba sterol 14α-demethylase (CYP51) is an essential enzyme of the sterol biosynthetic pathway. Repurposing antifungal azoles for amoebic infections has been reported, but their inhibitory effects on Acanthamoeba CYP51 enzymatic activity have not been studied. Here, we report catalytic properties, inhibition, and structural characterization of CYP51 from Acanthamoeba castellanii. The enzyme displays a 100-fold substrate preference for obtusifoliol over lanosterol, supporting the plant-like cycloartenol-based pathway in the pathogen. The strongest inhibition was observed with voriconazole (1 h IC50 0.45 μM), VT1598 (0.25 μM), and VT1161 (0.20 μM). The crystal structures of A. castellanii CYP51 with bound VT1161 (2.24 Å) and without an inhibitor (1.95 Å), presented here, can be used in the development of azole-based scaffolds to achieve optimal amoebicidal effectiveness.
Insights
Acanthamoeba infections require new drugs. Researchers studied Acanthamoeba sterol 14α-demethylase (CYP51) and found azole drugs like VT1161 show strong inhibition, aiding new treatment development.
Area of Science:
- Biochemistry
- Parasitology
- Structural Biology
Background:
- Acanthamoeba causes severe infections like keratitis and encephalitis.
- Developing safe and effective drugs against Acanthamoeba is a critical need.
- Antifungal azoles have been explored for amoebic infections, but their direct enzyme inhibition is unstudied.
Purpose of the Study:
- To characterize the catalytic properties and inhibition of Acanthamoeba castellanii sterol 14α-demethylase (CYP51).
- To determine the structural basis for inhibitor binding to A. castellanii CYP51.
- To evaluate the potential of repurposed azoles as amoebicidal agents.
Main Methods:
- Enzyme kinetics assays to determine substrate preference and inhibition constants.
- Crystallography to obtain the structures of A. castellanii CYP51 with and without inhibitors.
- Structure-based drug design principles.
Main Results:
- A. castellanii CYP51 shows a 100-fold preference for obtusifoliol over lanosterol, indicating a plant-like sterol pathway.
- Voriconazole, VT1598, and VT1161 demonstrated potent inhibition of CYP51 activity.
- Crystal structures revealed inhibitor binding modes, providing a basis for scaffold development.
Conclusions:
- Repurposed azoles, particularly VT1161, show significant promise for treating Acanthamoeba infections.
- Structural insights into A. castellanii CYP51 facilitate the design of novel amoebicidal drugs.
- Targeting CYP51 is a viable strategy for developing new therapies against blinding and fatal amoebic diseases.
More Related Videos
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
07:33Author Spotlight: Studying Behavior of Acanthamoeba to Develop Targeted Strategies for Preventing Acanthamoeba Keratitis
Published on: September 20, 2024
Related Concept Videos
Enzyme Inhibition
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Inhibitors of Bacterial Protein Synthesis
Antifungal Agents
Anthelminthic Agents